While Eugia continues to look for ways to solve the future challenges amidst temporary plant closure, parent Aurobindo reported a “good” performance in FY2024, with expected continued growth, and gave an update on its Auro Peptides business and GLP-1s.

While outlining key dates for its biosimilars portfolio, Aurobindo remains confident in the US market stability for its products.

Known for its efforts in neurology, Biogen has been looking to make somewhat safer bets in immunology as it seeks to diversify and may achieve that with HI-Bio’s Phase III-ready felzartamab. 

With originator Xolair’s patents already expired or about to end next year, Aurobindo’s CuraTeQ is on track with its omalizumab biosimilar for regulatory filings in 2024/2025, following a Phase I trial completion.